TY - JOUR
T1 - Rekombinant faktor VIIa ved post partum-blødning
AU - Wikkelsø, Anne Juul
AU - Stensballe, Jakob
PY - 2022/11/21
Y1 - 2022/11/21
N2 - Recombinant factor VIIa (rFVIIa) has of April 2022 been approved by the European Medicines Agency for treatment of severe postpartum haemorrhage. The extended approval is based on one small open-label, non-blinded randomized trial of 84 women from 2015 showing reduced "second line" treatment, but also increased risk of thromboembolism. Systematic use of tranexamic acid and timely coagulation assessment with thromboelastography/rotational thromboelastometry are not applied. Danish and international societies recommend that rFVIIa is reserved as a last option in severe life-threatening cases of postpartum haemorrhage.
AB - Recombinant factor VIIa (rFVIIa) has of April 2022 been approved by the European Medicines Agency for treatment of severe postpartum haemorrhage. The extended approval is based on one small open-label, non-blinded randomized trial of 84 women from 2015 showing reduced "second line" treatment, but also increased risk of thromboembolism. Systematic use of tranexamic acid and timely coagulation assessment with thromboelastography/rotational thromboelastometry are not applied. Danish and international societies recommend that rFVIIa is reserved as a last option in severe life-threatening cases of postpartum haemorrhage.
KW - Female
KW - Humans
KW - Factor VIIa/therapeutic use
KW - Postpartum Hemorrhage/drug therapy
KW - Recombinant Proteins/therapeutic use
KW - Randomized Controlled Trials as Topic
UR - https://ugeskriftet.dk/videnskab/rekombinant-faktor-viia-ved-postpartum-blodning
UR - http://www.scopus.com/inward/record.url?scp=85142612801&partnerID=8YFLogxK
M3 - Tidsskriftartikel
C2 - 36426830
SN - 0041-5782
VL - 184
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
IS - 47
M1 - V07220423
ER -